Phase 1 Solid Tumors, Adult Clinical Trials
11 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company880 enrolled66 locationsNCT05768139
Recruiting
Phase 1
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Solid Tumors, Adult
Grit Biotechnology31 enrolled5 locationsNCT05430373
Recruiting
Phase 1
HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
Solid Tumors, Adult
HighField Biopharmaceuticals Corporation84 enrolled2 locationsNCT05861895
Recruiting
Phase 1Phase 2
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Solid Tumors, Adult
Hutchmed186 enrolled11 locationsNCT07396584
Recruiting
Phase 1Phase 2
A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Solid Tumors, Adult
Abbisko Therapeutics Co, Ltd401 enrolled1 locationNCT07417189
Recruiting
Phase 1
Imaging of Solid Tumors Using FAP-2286
Metastatic CancerSolid Tumors, Adult
Thomas Hope191 enrolled1 locationNCT04621435
Recruiting
Phase 1Phase 2
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Solid Tumors, Adult
Hutchmed147 enrolled11 locationsNCT07228247
Recruiting
Phase 1
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Solid Tumors, Adult
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company32 enrolled2 locationsNCT06504368
Recruiting
Phase 1
TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Solid Tumors, Adult
Grit Biotechnology12 enrolled1 locationNCT06088472
Recruiting
Phase 1Phase 2
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316
Recruiting
Phase 1
PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors
Solid Tumors, Adult
Shenzhen Celconta Life Science Co., Ltd.18 enrolled1 locationNCT06897228